Owing to the innovative approach adopted by Dr. Yang Liu and OncoC4 developing unique drugs that uncouple therapeutic effects and immunotherapy-related adverse effects, Dr. Liu is being featured in the “Top 20 Dynamic CEOs of 2022″ edition. Adam Patrick, Managing Editor of The CEO Publication, says, “Dr. Yang Liu’s love of science and appreciation of others’ talents attract a diverse team of successful business, clinical and regulatory executives, and biopharmaceutical researchers and inspire the team to work together, hence he is being featured as one of the Top 20 Dynamic CEOs of 2022 who is a true inspiration.”
Full article can be found here: "Leading with Research & Innovation | Dr. Yang Liu"
